EGFR TKI (1st generation) · small molecule

icotinib

5 active trials, targeting EGFR. Not approved for any biomarker on marked.bio yet.

Also known as BPI-2009, Conmana.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

Biomarker	Active trials	All trials	Furthest active phase
EGFR exon 19 deletion / L858R	5	56	Phase 3

Trials

5 of 56 trials shown

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Recruiting Phase 3 Betta Pharmaceuticals Started 2023Primary completion 2028-04 NCT06041776

befotertinibicotinib

…bors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).

EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2023-09-22Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

Recruiting Phase 2 Sun Yat-sen University Started 2024Primary completion 2026-07 NCT06517953

icotinibbefotertinib

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2024-07-25Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q, EGFR S768I
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

Not yet recruiting Phase 2 Liaoning Cancer Hospital & Institute Started 2022Primary completion 2024-07 NCT05132985

icotinibcisplatincarboplatinpemetrexed

A tumor which harbors either Ex19del or L858R EGFR-TKI-sensitizing mutations, either alone

EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2021-12-10NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2021Primary completion 2024-03 NCT05104788

icotinibcisplatincarboplatinpemetrexed

…d with EGFR-TKI （epidermal growth factor receptor tyrosine kinase inhibitors）sensitivity (Ex19del, L858R).

EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2021-11-03Non-Small Cell Lung Cancer
Therapy for Advanced NSCLC With EGFR 19delins Mutation

Not yet recruiting Early Phase 1 Fuzhou General Hospital Started 2026Primary completion 2030-10 NCT07458919

icotinibgefitinib FDA EUbefotertinibosimertinib FDA EUfurmonertinib

Epidermal growth factor receptor (EGFR) exon 19 deletion-insertion mutation (19delins) documented by testing of tumor tissue or plasma samples usi…

EGFR exon 19 deletion / L858RLung Cancer
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study

Unknown status Phase 4 Tian Xie Started 2020 NCT04401059

Elemene plus first or third generation EGFR-TKIsgefitinib FDA EUerlotinib FDA EUicotinibosimertinib FDA EUaumolertinibfurmonertinib

Patients with EGFR mutations (deletions in exon 19 and L858R in exon 21 of the EGFR gene), plan to receive First-generation EGFR-TKIs (Gefit…

EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Unknown status Phase 4 Betta Pharmaceuticals Started 2014 NCT02103257

icotinibpemetrexed

EGFR activating mutation (exon 19 deletion, L858R) is required

EGFR exon 19 deletion / L858REGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer

Unknown status Phase 4 Qilu Hospital of Shandong University Started 2014 NCT02031601

erlotinib FDA EUgefitinib FDA EUicotinibdocetaxelpemetrexedcisplatincarboplatin

EGFR mutation-positive (EGFR exon-18, exon-19 or exon-21);

EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

Unknown status Phase 4 Betta Pharmaceuticals Started 2014 NCT02194556

icotinibgemcitabine

Positive EGFR Mutation

EGFR exon 19 deletion / L858REGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

Unknown status Phase 4 Chinese PLA General Hospital Started 2014 NCT02283424

icotinibcarboplatindocetaxel

Lung adenocarcinoma patients with epidermal growth factor receptor gene mutation,stage I-IIIB after surgery

EGFR exon 19 deletion / L858RNeoplasms, Therapy-Associated
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Unknown status Phase 4 Betta Pharmaceuticals Started 2012 NCT01665417

icotinibpemetrexeddocetaxel

Patients must have lung cancer with a documented EGFR activating mutation (exon 19 deletion, L858R).

EGFR exon 19 deletion / L858REGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

Unknown status Phase 4 Betta Pharmaceuticals Started 2012 NCT01646450

icotinib

Positive EGFR Mutation.

EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC

Unknown status Phase 3 Tianjin Medical University Cancer Institute and Hospital Started 2021 NCT04797806

anlotinibicotinib

…rent non-squamous NSCLC（according to the 8th Edition of the AJCC Staging system）with EGFR 19 del or 21 L858R gene mutation and concomitant others.

EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Completed Phase 2/3 Betta Pharmaceuticals Started 2019 NCT04206072

befotertinibicotinib

…ur one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations, assessed by central la…

EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer, EGFR Gene Mutation
Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

Unknown status Phase 3 Tianjin Medical University Cancer Institute and Hospital Started 2019 NCT03992885

icotinibpemetrexed

Metastatic non-squamous non-small cell lung cancer with EGFR mutations confirmed by histological or cytological examination;

EGFR exon 19 deletion / L858RNon-squamous Non-small Cell Lung Cancer
A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy

Unknown status Phase 3 Betta Pharmaceuticals Started 2018 NCT04058704

icotinib

Positive EGFR mutation（Ex19del or 21L858R）

EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer, Brain Metastases
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation

Unknown status Phase 3 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Started 2016 NCT02883543

icotinibChemotherapy

Positive EGFR mutation confirmed by ARMS

EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)

Unknown status Phase 3 Sichuan Provincial People's Hospital Started 2015 NCT02882984

gefitinib FDA EUerlotinib FDA EUicotinib

Positive EGFR mutation.

EGFR exon 19 deletion / L858RStage IV EGFR Mutated NSCL With Brain Metastases
EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Unknown status Phase 3 Sun Yat-sen University Started 2015 NCT02714010

gefitinib FDA EUerlotinib FDA EUicotinib

… who was confirmed non-small cell lung cancer (NSCLC) by histology or cytology, harboring EGFR mutant type (19 and/or 21 exon mutation).

EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Unknown status Phase 3 Betta Pharmaceuticals Started 2015 NCT02448797

icotinibvinorelbinepemetrexed

Positive EGFR gene mutation (19/21)

EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation

Terminated Phase 3 Sun Yat-sen University Started 2014 NCT01996098

icotinib

EGFR activating mutation in exon 19 or 21.

EGFR exon 19 deletion / L858RLung Cancer
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

Unknown status Phase 3 Betta Pharmaceuticals Started 2014 NCT02125240

icotinib

Patients must harbor sensitive EGFR gene mutation (19/21)

EGFR exon 19 deletion / L858REGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

Completed Phase 3 Guangdong Association of Clinical Trials Started 2012 NCT01724801

icotinib

Patient who was confirmed stage IV NSCLC with EGFR activating mutation and brain metastases by pathologic histology or cytology.

EGFR exon 19 deletion / L858RBrain Metastasis, Non Small Cell Lung Cancer
Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Completed Phase 3 Betta Pharmaceuticals Started 2012 NCT01719536

icotinibpemetrexed

Positive EGFR Mutation.

EGFR exon 19 deletion / L858RNSCLC
Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Completed Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2022 NCT05263947

bevacizumabicotinib

Documented EGFR exon 21 L858R mutation, as centrally confirmed by a high-sensitivity PCR-based test on tumor tissue.

EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung, Bevacizumab, Tyrosine Kinase Inhibitor, EGFR L858R
A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection

Unknown status Phase 2 Wu Nan Started 2022 NCT05514314

icotinib

A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) ,without KRAS mutation

EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Unknown status Phase 2 Betta Pharmaceuticals Started 2021 NCT05007938

icotinibbefotertinib

…ur one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R),either alone or in combination with other EGFR mutations, excluding co-mutation o…

EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

Unknown status Phase 2 Betta Pharmaceuticals Started 2018 NCT03349203

icotinib

EGFR mutation (EGFR 19del and/or 21L858R) detected by tumor tissue biopsy of primary lesion or metastatic lesion or…

EGFR exon 19 deletion / L858REGF-R Positive Non-Small Cell Lung Cancer
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

Unknown status Phase 2 Betta Pharmaceuticals Started 2018 NCT03749213

icotinib

EGFR mutation (EGFR 19del and/or 21L858R) detected by tumor tissue biopsy of primary lesion or metastatic lesion or…

EGFR exon 19 deletion / L858REGF-R Positive Non-Small Cell Lung Cancer
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Unknown status Phase 2 Betta Pharmaceuticals Started 2018 NCT03396185

icotinib

…er, histology or cytology confirmed lung adenocarcinoma, pathological specimens with EGFR 19 del and/or 21 L858R gene mutation detected by amplification refractory mutation system method

EGFR exon 19 deletion / L858REGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA, Non Small Cell Lung Cancer Stage IIIB
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Completed Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2018 NCT03736837

anlotinibicotinib

…rent non-squamous NSCLC（according to the 8th Edition of the AJCC Staging system）with EGFR 19 del and/or 21 L858R gene mutation

EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Unknown status Phase 2 Betta Pharmaceuticals Started 2018 NCT03754530

icotinib

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer, Brain Metastases
Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC

Unknown status Phase 2 Peking University Cancer Hospital & Institute Started 2018 NCT03402464

icotinib

Sensitive EGFR gene mutation(19/21)

EGFR exon 19 deletion / L858REGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma
Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer

Unknown status Phase 2 Betta Pharmaceuticals Started 2017 NCT03346811

icotinib

Plasma EGFR mutations (EGFR 19del and/or 21L858R) positive (simultaneously detected by Super-ARMS, ddPCR and NGS，any positi…

EGFR exon 19 deletion / L858RPlasma EGFR Mutation-positive Lung Cancer
Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation

Unknown status Phase 2 Sichuan Cancer Hospital and Research Institute Started 2017 NCT03153358

icotinib

Histologic documentation of primary lung carcinoma, non-squamous histology with EGFR mutation.

EGFR exon 19 deletion / L858RLung Cancer Stage IV
A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Unknown status Phase 2 First People's Hospital of Hangzhou Started 2016 NCT02788058

gefitinib FDA EUerlotinib FDA EUicotinib

…wly diagnosed metastatic lung adenocarcinoma harboring sensitizing EGFR mutations (L858R, exon 19 deletion), and became oligometastatic disease after 3 months TKI, evaluated by PET/CT scan, brain …

EGFR exon 19 deletion / L858RLung Adenocarcinoma, EGFR Positive Non-small Cell Lung Cancer
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

Unknown status Phase 2 First People's Hospital of Hangzhou Started 2016 NCT02787447

gefitinib FDA EUerlotinib FDA EUicotinibThymosin Alpha 1

…wly diagnosed metastatic lung adenocarcinoma harboring sensitizing EGFR mutations (L858R, exon 19 deletion), and showed stable disease after 3 months TKI, evaluated twice by PET/CT scan, brain MRI…

EGFR exon 19 deletion / L858RLung Adenocarcinoma
High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Unknown status Phase 2 Betta Pharmaceuticals Started 2016 NCT02726568

icotinib

Positive EGFR mutation（Ex19del or 21L858R）.

EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer, Brain Metastases
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation

Unknown status Phase 2 Beijing Haidian Hospital Started 2016 NCT02820116

icotinib

Pathologically confirmed non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858 mutation.

EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer(NSCLC)
Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Unknown status Phase 2 Henan Cancer Hospital Started 2016 NCT02737774

icotinibpemetrexedcarboplatin

Positive EGFR mutation(19 exon or 21 exon)。

EGFR exon 19 deletion / L858RLung Adenocarcinoma
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Unknown status Phase 2 Chinese Academy of Medical Sciences Started 2016 NCT02960607

icotinib

are EGFR mutation-positive or

EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Completed Phase 2 Shanghai Chest Hospital Started 2015 NCT03544814

icotinibpemetrexedcisplatin

Sensitive EGFR mutations (exon 19 deletion or L858R mutation in exon 21)

EGFR exon 19 deletion / L858RLung Adenocarcinoma, EGFR Activating Mutation
Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

Unknown status Phase 2 Zhejiang University Started 2015 NCT02375022

icotinib

…ncer, with activating epidermal growth factor receptor (defined as deletion 19 or exon 21 L858R mutation).

EGFR exon 19 deletion / L858RLung Cancer
Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Unknown status Phase 2 Sun Yat-sen University Started 2015 NCT03151161

icotinibpemetrexedcarboplatin

Confirmed activating mutation of EGFR-ie, an exon 19 deletion or an exon 21 L858R point mutation.

EGFR exon 19 deletion / L858RLung, Carcinoma
Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Completed Phase 2 Sun Yat-sen University Started 2015 NCT02264210

icotinib

EGFR activating mutation in exon 19 or 21.

EGFR exon 19 deletion / L858RLung Neoplasms, Squamous Cell Lung Cancer, Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer

Unknown status Phase 2 Nanfang Hospital, Southern Medical University Started 2014 NCT02272127

icotinib

Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer

EGFR exon 19 deletion / L858RNSCLC
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer

Unknown status Phase 2 People's Hospital of Guangxi Zhuang Autonomous Region Started 2014 NCT02407366

icotinibpemetrexedcarboplatin

…Unresectable Stage III Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor ( EGFR) Mutation

EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation

Completed Phase 2 Betta Pharmaceuticals Started 2014 NCT02044328

icotinib

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation

EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

Unknown status Phase 2 Betta Pharmaceuticals Started 2013 NCT01843647

icotinibvinorelbinecisplatin

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

EGFR exon 19 deletion / L858RNon-small-cell Lung Cancer
Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

Unknown status Phase 2 Betta Pharmaceuticals Started 2013 NCT01929200

icotinib

…cotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

EGFR exon 19 deletion / L858RNon-small-cell Lung Cancer
Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer

Unknown status Phase 2 Zhejiang Cancer Hospital Started 2012 NCT01688713

icotinib

Patients with EGFR mutation or the lesions that remains stable for more than 3 months after local treatment(WBRT and/…

EGFR exon 19 deletion / L858RBrain Metastases, Non-small Cell Lung Cancer
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Completed Phase 1/2 Betta Pharmaceuticals Started 2011 NCT01516983

icotinib

Positive EGFR mutation.

EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer, Brain Metastases
Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Unknown status Phase 1 Betta Pharmaceuticals Started 2014 NCT02066870

icotinibArsenic trioxide

Histologically or cytologically confirmed stage IIIB/IV lung cancer with EGFR mutation

EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Unknown status No phase The First Affiliated Hospital of Soochow University Started 2019 NCT03766490

anlotinibgefitinib FDA EUicotinib

Previously, EGFR gene test showed EGFR exon 19 deletion or exon 21 (L858R) mutation, and the gene test showed no T790M mutation before enrollment…

EGFR exon 19 deletion / L858RNon-Small-Cell Lung
Adjuvant Chemotherapy With or Without Intercalated Icotinib

Unknown status No phase Nanfang Hospital, Southern Medical University Started 2019 NCT03983811

icotinib

Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients With or Without Intercalated Icotinib Therapy: a Rand…

EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Unknown status No phase Guangdong Association of Clinical Trials Started 2019 NCT04007835

anlotinibgefitinib FDA EUerlotinib FDA EUicotinib

The patients should be confirmed with EGFR mutation \[e.g., T 790 M , exon 19 deletion, L 858 R, etc\],

EGFR exon 19 deletion / L858RNSCLC

Biomarkers

Sponsors

Trials